Anavex Life Sciences (AVXL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 20/100 (LOW), 43.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.11% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial
- Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome
- Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
- PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences
- PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance
- PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign
- Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
- PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Anavex Life Sciences.
Full AVXL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.